ContraFect Corp Overview
Pro stress-test →ContraFect Corp was a clinical-stage biotechnology company focused on developing novel therapeutics for drug-resistant, life-threatening infectious diseases. The company pioneered direct lytic agents (lysins and amurin peptides) as new medical modalities to combat antibiotic-resistant pathogens. However, the company filed for Chapter 7 liquidation in December 2023.
Strategic Profile
Pro stress-test →ContraFect's innovation centered on bacteriophage-derived lysins targeting conserved bacterial regions resistant to mutation, with lead candidate exebacase (CF-301) for prosthetic joint infections and CF-370 for gram-negative pathogens. The company held a license agreement with The Rockefeller University for gram-negative lysin research. Operations ceased following liquidation filing.
Competitive Landscape
Pro stress-test →ContraFect competed in the antibiotic resistance therapeutics space against traditional small-molecule antibiotic developers, monoclonal antibody platforms (Regeneron, GSK), and other novel modality companies (phage therapy platforms, antimicrobial peptides). Its differentiation through bacteriophage lysins offered a novel mechanism but failed to achieve regulatory or commercial success.
Industry Context
ContraFect Corp operates in Biotechnology / Infectious Disease Therapeutics.
Key facts
Founded: 2008 · Headquarters: Yonkers, US · Employees: 23 · Revenue: N/A · Market cap: N/A